Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: Role for proteins involved in resistance to apoptosis and hypoxia

Histopathology

Volumn 60, Issue 3, 2012, Pages 460-471

  Santacana, Maria ^a   Yeramian, Andree ^a   Velasco, Ana ^a   Bergada, Laura ^a   Gatius, Sonia ^a   García, Virginia ^a   Azueta, Ainara ^a,b   Palacios, Jose ^b   Dolcet, Xavier ^a   Oliva, Esther ^c   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Apoptosis; Endometrial carcinoma; Hypoxia; Tissue microarray; Vaginal recurrence

Indexed keywords

BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANOXIA; APOPTOSIS; BETA CATENIN; CARCINOMA, ENDOMETRIOID; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CELL NUCLEUS; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; TISSUE ARRAY ANALYSIS; VAGINAL NEOPLASMS;

EID: 84856252570     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04106.x     Document Type: Article

References (37)

1. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 15; 10-17.
2. Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 2001; 32; 569-577.
3. Catasus L, Gallardo A, Cuatrecasas M et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod. Pathol. 2009; 22; 522-529.
4. Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2004; 92; 744-751.
5. Yeramian A, Santacana M, Sorolla A et al. Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner. Lab. Invest. 2011; 91; 859-871.
6. Catasús Ll, Machín P, Matias-Guiu X et al. Microsatellite instability in endometrial carcinomas: clinico-pathologic correlations in a series of 42 cases. Hum. Pathol. 1998; 29; 1160-1164.
7. Bussaglia E, del Rio E, Matias-Guiu X et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum. Pathol. 2000; 31; 312-317.
8. Velasco A, Bussaglia E, Pallares J et al. PIK3CA gene mutations in endometrial carcinoma. Hum. Pathol. 2006; 37; 1465-1472.
9. Lagarda H, Catasus Ll, Argüelles RM et al. k-RAS mutations in endometrial carcinomas with microsatellite instability. J. Pathol. 2001; 193; 193-199.
10. Machin P, Catasus L, Pons C et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum. Pathol. 2002; 33; 206-212.
11. Tavasoli FA, Devilee P. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female organs. Lyon: IARC Press, 2003.
12. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int. J. Gynecol. Obstet. 2009; 105; 109-110.
13. Pallares J, Martínez-Guitarte JL, Dolcet X et al. Abnormalities in NF-κB family and related proteins in endometrial carcinoma. J. Pathol. 2004; 204; 569-577.
14. Pallares J, Martínez-Guitarte JL, Dolcet X et al. Survivin expression in endometrial carcinoma. Int. J. Gynecol. Pathol. 2005; 24; 247-253.
15. Dolcet X, Llobet D, Pallares J et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab. Invest. 2005; 85; 885-894.
16. Pallares J, Llobet D, Santacana M et al. CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am. J. Pathol. 2009; 174; 287-296.
17. Pallarés J, Velasco A, Eritja N et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod. Pathol. 2008; 21; 691-699.
18. Pallares J, Santacana M, Puente S et al. A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma. Anal. Quant. Cytol. Histol. 2009; 31; 217-226.
19. Pijnenborg JM, Romano A, Dam-de Veen GC et al. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J. Pathol. 2005; 205; 597-605.
20. Pijnenborg JM, Dam-de Veen GC, de Haan J et al. Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol. Oncol. 2004; 94; 550-559.
21. Pijnenborg JM, van de Broek L, Dam de Veen GC et al. TP53 overexpression in recurrent endometrial carcinoma. Gynecol. Oncol. 2006; 100; 397-404.
22. Pijnenborg JM, Kisters N, van Engeland M et al. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int. J. Gynecol. Cancer 2004; 14; 947-956.
23. Pijnenborg JM, Wijnakker M, Hagelstein J et al. Hypoxia contributes to development of recurrent endometrial carcinoma. Int. J. Gynecol. Cancer 2007; 17; 897-904.
24. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004; 5; 405-406.
25. Harada H, Kizaka-Kondoh S, Li G et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007; 26; 7508-7516.
26. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004; 25; 280-288.
27. Chen F, Castranova V, Shi X et al. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 2001; 59; 387-397.
28. Thome M., Schneider P. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386; 517-521.
29. Mawji IA, Simpson CD, Hurren R et al. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J. Natl Cancer Inst. 2007; 99; 811-822.
30. Luo A, Wang W, Sima N et al. Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. Cancer Lett. 2008; 271; 323-332.
31. Ahmed KM, Li JJ. NF-kB mediated adaptative resistance to ionizing radiation. Free Radic. Biol. Med. 2008; 44; 1-13.
32. Ahmed K, Li JJ. ATM-NF-kB connection as a target for tumor radiosensitization. Curr. Cancer Drug Targets 2007; 7; 335-342.
33. Moreno-Bueno G, Hardisson D, Prat J et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002; 21; 7981-7990.
34. Schlosshauer PW, Pirog EC, Levine RL et al. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod. Pathol. 2000; 13; 1066-1071.
35. Woodward WA, Chen MS, Behbod F et al. WNT/beta-catenin mediates radiation resistance of mouse progenitor cells. Proc. Natl Acad. Sci. USA 2007; 104; 618-623.
36. Katayama R, Ishioka T, Takada S et al. Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L. J. Cell Sci. 2010; 123; 23-28.
37. Ullenhag GJ, Mukherjee A, Watson NF et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 2007; 13; 5070-5075.